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Abstract: Vitamin E is an essential vitamin and a lipid soluble antioxidant, at least, under 
in vitro conditions. The antioxidant properties of vitamin E are exerted through its phenolic 
hydroxyl group, which donates hydrogen to peroxyl radicals, resulting in the formation of 
stable lipid species. Beside an antioxidant role, important cell signalling properties of 
vitamin E have been described. By using gene chip technology we have identified α-
tocopherol sensitive molecular targets in vivo including christmas factor (involved in the 
blood coagulation) and 5α-steroid reductase type 1 (catalyzes the conversion of 
testosterone to 5α-dihydrotestosterone) being upregulated and Ȗ-glutamyl-cysteinyl 
synthetase (the rate limiting enzyme in GSH synthesis) being downregulated due to α-
tocopherol deficiency. α-Tocopherol regulates signal transduction cascades not only at the 
mRNA but also at the miRNA level since miRNA 122a (involved in lipid metabolism) and 
miRNA 125b (involved in inflammation) are downregulated by α-tocopherol. Genetic 
polymorphisms may determine the biological and gene-regulatory activity of α-tocopherol. 
In this context we have recently shown that genes encoding for proteins involved in 
peripheral α-tocopherol transport and degradation are significantly affected by the apoE 
genotype. 
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1. Introduction, Chemistry and Antioxidant Properties of Vitamin E 
Vitamin E was discovered at the University of California at Berkeley in 1922 in the laboratory of 
Herbert M. Evans (Figure 1). Eight vitamin E isoforms with biological activity have been isolated 
from plant and animal sources. Tocopherols are part of an interlinking set of antioxidant cycles, which 
has been termed the so-called antioxidant network [9]. Since its discovery, mainly antioxidant and 
recently also cell signalling aspects of tocopherols have been studied. Advances in gene chip and 
miRNA technology have led to the discovery of novel vitamin E-sensitive genes and vitamin E 
regulated signal transduction pathways. Polymorphisms in genes involved in tocopherol tissue uptake, 
export, and metabolism may be important determinants for the biological activity of vitamin E.  
Figure 1. Milestones in vitamin E research. 
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Vitamin E consists of a mixture of tocopherols and tocotrienols that are synthesised by plants from 
homogenestic acid. All are derivatives of 6-chromanol with an aliphatic side-chain. The four 
tocopherol homologues (α-, β-, γ-, δ-) have a fully saturated 16-carbon isoprenoid side-chain, whereas 
tocotrienols have a similar isoprenoid chain containing three double bonds. Individual tocopherols are 
named according to the position and number of the methyl groups on the phenol ring, with the α-, β-, γ- and δ- vitamins containing three, two, two and one methyl groups respectively (Figure 2). These 
structural differences determine the biological activity, with α-homologues being the most biologically 
active [10].  
The antioxidant property of vitamin E is exerted through the phenolic hydroxyl group, which 
readily donates its hydrogen to the peroxyl radical, resulting in the formation of a stable lipid species. 
In donating the hydrogen atom, vitamin E becomes a relatively unreactive free radical as the unpaired 
electron becomes delocalised into the aromatic ring. The efficiency of this protection depends upon 
two factors: firstly the mobility of the molecule in membranes, which is determined by the aliphatic 
tail; secondly the number of methyl species on the chromanol ring, with each methyl group conferring 
additional antioxidant capacity. In addition, the proximity of the methyl species to the hydroxyl group 
is an important factor. Therefore α-homologues, which have the greatest number of methyl species, 
and in which these flank the hydroxyl group, are thought to be more effective than the other 
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homologues. Nevertheless, in several in vitro studies a reverse order of antioxidant efficacy with α-
tocopherol being the least potent compound as compared to δ- and γ-tocopherol has been observed 
[11–15]. Furthermore, in superiority to α-tocopherol, γ-tocopherol and other non-α-tocopherols are 
able to trap membrane-soluble electrophilic nitrogen oxides and other electrophilic mutagens 
possessing free aromatic ring positions and thereby more efficiently inhibiting reactive nitrogen 
species derived damage [16,17]. 
Figure 2. Molecular structure of vitamin E stereoisomers. 
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Vitamin E does not work in isolation from other antioxidants; rather it is part of an interlinking set 
of redox antioxidants, as summarized in Figure 3. The antioxidant activity of vitamin E has been 
detailed many times (e.g., [18]). In this regard vitamin E is able to scavenge peroxyl radicals 
essentially neutralizing them to form hydroperoxides. Lipid peroxyl radicals are formed during lipid 
peroxidation. Following an initiating event induced by, for example, a reactive oxygen species, a 
hydrogen molecule is abstracted from a C-H bond that has been weakened due to the proximity to an 
electron withdrawing double bond found in polyunsaturated fatty acids forming a carbon-centered 
radical. During this process there is molecular rearrangement of the lipid to a conjugated diene 
structure and addition of O2 to the carbon-centered radical giving rise to a lipid peroxyl radical. This 
radical is highly reactive and if not quenched will react with a nearby polyunsaturated fatty acid 
causing another initiating event and hence propagating lipid peroxidation. As a scavenger of peroxyl 
radicals vitamin E is acting to inhibit this chain reaction which is why it is termed a chain-breaking 
lipid antioxidant. Without vitamin E activity a single initiating event could potentially lead to the 
production of thousands of lipid peroxides which would have a deleterious effect on the biological 
membrane and its function. The sequence of events can be seen as: 
(1) -LH + ROS ? L 
(2) -L
.
 + O2 ? -LOO. 
(3) -LOO
.
 + VEH ? LOOH + VE. 
It is hypothesized that vitamin E acts catalytically, being efficiently reduced from its free radical 
(chromanoxyl) form that arises after quenching lipid radicals to return back to its reduced native state. 
This catalysis occurs through the interactions between water- and lipid-soluble substances by both 
nonenzymatic and enzymatic mechanisms that regenerate vitamin E from its tocotrienoxyl or 
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tocopheroxyl radical back to tocotrienol and tocopherol respectively. Vitamin C can regenerate 
vitamin E directly, and thiol antioxidants, such as glutathione and lipoic acid, can regenerate vitamin E 
indirectly via vitamin C. Under conditions where these systems act synergistically to keep the steady-
state concentration of vitamin E radicals low, the loss or consumption of vitamin E is prevented [9]. 
Previous studies in cultured cells indicate synergistic effects between polyphenols and vitamin E  
(Ȗ-tocopherol but not α-tocopherol) in vitro [19]. However, dietary supplementation of growing pigs 
with green tea polyphenols did not affect serum, liver, lung and muscle vitamin E (α- and γ-
tocopherol) concentrations, plasma antioxidant capacity [20]. Furthermore, also in rats [21] and 
humans [22] no vitamin E (α- and γ-tocopherol) sparing effect of dietary flavonoids was evident. 
Figure 3. The antioxidant network showing the interaction among vitamin E, vitamin C 
and thiol redox cycles (according to [9]) © American Society for Nutrition); PUFA: 
polyunsaturated fatty acid, ROOH: lipid peroxide, ROH: alcohol, ROO: peroxyl radical; 
RO: alkoxyl radical, O2
−
: superoxide anion radical, NAD(P)H: nicotinamide-adenine-
dinucleotide-(phosphate).   
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2. Gene Regulatory Activity of Vitamin E 
Since its discovery, mainly antioxidant and recently also cell signalling aspects of tocopherols have 
been studied. Vitamin E is a cell signalling molecule [23]. It interacts with cell receptors (e.g., LDL-
receptor) and transcription factors (e.g., pregnane X receptor) thereby driving (redox-regulated) gene 
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expression (e.g., scavenger receptor CD36). It modulates protein levels (e.g., glutathione) and changes 
enzyme activity levels (e.g., protein kinase C) both in cultured cells as well as in vivo (Figure 4).  
 
Figure 4. Vitamin E is a cell signalling molecule and affects cell receptors, transcription 
factors, gene expression, protein levels and enzyme activities of vitamin E specific 
molecular targets. 
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Azzi's group [5,24,25] first described non-antioxidant cell signalling functions for α-tocopherol, 
demonstrating that vitamin E inhibits protein kinase C (PKC) and 5-lipoxygenase and activates protein 
phosphatase 2A and diacylglycerol kinase. Some genes including α-tocopherol transfer protein  
(α-TTP), α-tropomyosin, and collagenase are affected by α-tocopherol at the transcriptional level. 
To obtain a comprehensive understanding of the molecular mechanisms of action of vitamin E, 
global gene expression profile experiments using DNA arrays in rat liver and hepatocellular liver 
carcinoma cells (HepG2) have been conducted.  
For the analysis of short-term (49 days) [26] and long-term (290 days) vitamin E deficiency [27], 
rats were fed semisynthetic diets either supplemented with or deficient in vitamin E (DL-α-tocopheryl 
acetate [26]; RRR-α-tocopheryl acetate [27]). In addition, HepG2 cells were treated with vitamin E 
(RRR-α-tocopheryl acetate) concentrations comparable to those that were achieved in the in vivo 
experiment [28]. Differential gene expression in rat liver and that in HepG2 cells were measured by 
DNA arrays comprising up to 7,000 genes. Dietary vitamin E deficiency over a 7-week period did not 
induce any significant changes in the expression profile among the genes evaluated. However, long-
term vitamin E deficiency upregulated coagulation factor IX (FIX), 5-α-steroid reductase type 1, and 
CD36 mRNA levels. Furthermore, vitamin E deficiency resulted in a significant downregulation of 
hepatic Ȗ-glutamyl-cysteinyl synthetase, the rate-limiting enzyme of glutathione synthesis. 
Measurement of the corresponding biological endpoints such as activated partial thromboplastin time, 
plasma dihydrotestosterone and hepatic glutathione substantiated the gene chip data which indicated 
that dietary vitamin E plays an important role in a range of metabolic processes within the liver. 
According to the rat experiment, vitamin E supplementation changed coagulation factor IX and CD36 
expression in HepG2 cells; thus, in vivo data could be partly confirmed with the in vitro model. 
Overall, our studies reveal that dietary vitamin E has important long-term effects on liver gene 
expression with potential downstream effects on extrahepatic tissues. 
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We have recently studied the short- and long-term effects of natural and synthetic vitamin E on 
cytochrome (CYP) P450 dependent gene expression using Affymetrix GeneChip technology. To this 
end, HepG2 hepatoma cells were incubated with 0, 10, 30, 80 and 300 μM RRR-tocopheryl acetate 
(natural vitamin E) or all-rac-tocopheryl acetate (synthetic vitamin E) for 7 days and the mRNA of 
CYP genes was quantified. The expression of only one (CYP20A1) of 14 CYP genes with detectable 
mRNA levels was dosedependently up-regulated. No differences in gene-regulatory activity were 
observed between RRR- and all-rac-α-tocopheryl acetate. To study the role of vitamin E in CYP gene 
expression in vivo, Fisher 344 rats were randomly assigned to either a vitamin E-enriched (RRR-
tocopheryl acetate) or –deficient diet. Neither in the vitamin E-enriched, nor in the vitamin E-deficient 
rats, were significant changes in the liver CYP mRNA levels observed. These data indicate that 
vitamin E did not appear to modulate cytochrome P450 mRNA expression in our HepG2 cells or our 
in rat study [29]. However, other studies demonstrate that α-tocopherol supplementation did increase 
mRNA level and activity of several CYP members in the liver of mice and rats [30,31]. 
In another set of experiment two groups of male rats were fed with either a diet deficient in α-
tocopherol or a control diet enriched with RRR-α-tocopheryl acetate. Differential gene expression in 
skeletal muscle was monitored at five time-points over 430 days, with all animals individually profiled 
[32]. Out of approximately 7,000 genes represented on the gene chip, 56 were found to be up-regulated 
in response to vitamin E in at least four consecutive time-points from as early as 91 days of deficiency. 
Up-regulated genes included muscle structure and extra cellular matrix genes, as well as anti-
oxidative, anti-inflammatory and anti-fibrotic genes. Our data show that molecular transcription might 
provide a very early marker to detect oncoming degenerative conditions in vitamin E deficiency. They 
provide further insight into possible molecular mechanisms underlying vitamin E deficiency in skeletal 
muscle, and reveal the activation of an intensive protection program that can explain the long 
maintenance of muscle structure during vitamin E deficiency. 
Furthermore in rat brain a significant number of genes were found to be regulated by vitamin E. 
These vitamin E sensitive genes encode for proteins associated with hormones and hormone 
metabolism, nerve growth, apoptosis, dopaminergic neurotransmission, and clearance of amyloid-ȕ 
and advanced glycated endproducts [33]. 
Our in vivo data in rats also indicate that dietary vitamin E (RRR-α-tocopheryl acetate) induces 
changes in steroidogenesis by affecting cholesterol homeostasis in testes and adrenal glands. In this 
context genes encoding for proteins involved in the uptake (LDL receptor) and de novo synthesis (e.g., 
7-dehydrocholesterol reductase, 3-hydroxy-3-methylgluteryl coenzyme A synthase, 3-hydroxy-3-
methylglutaryl coenzyme A reductase, isopentenyl diphosphate δ-isomerase, and farnesyl 
pyrophosphate synthetase) of cholesterol (Figure 5), the precursor of all steroid hormones, have been 
identified as vitamin E sensitive molecular targets [34]. 
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Figure 5. Transcriptional regulation of vitamin E target genes. 
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3. Comparative Quantification of Pharmacodynamic Parameters of RRR- vs. all-rac-α 
Tocopherol by Global Gene Expression Profiling 
Pharmacologically active compounds (e.g., from the groups of pharmaceutical drugs, cofactors or 
vitamins) often consist of two or more stereoisomers (enantiomers or diastereoisomers) which may 
differ in their pharmacodynamic/kinetic, toxicological and biological properties. A well-known 
example is vitamin E which is predominantly administered as two different forms, one derived from 
natural sources (mainly soybeans), and one from production by chemical total-synthesis. While 
vitamin E from natural sources occurs as a single stereoisomer (RRR-α-tocopherol), synthetic vitamin 
E (all-rac-α-tocopherol) is an equimolar mixture of eight stereoisomers. Based on a number of animal 
and human studies it has been suggested that the biological potency of natural-source vitamin E  
(RRR-) is 1.36 greater compared to its counterpart produced by chemical synthesis (all-rac) [35]. We 
have used the Affymetrix GeneChip technology to evaluate the feasibility of a new bio-assay where 
the gene regulatory activities of RRR-α-tocopherol and all-rac-α-tocopherol were quantified and 
compared on the genome-wide level [36]. For this purpose, HepG2 cells were supplemented with 
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increasing amounts of RRR- or all-rac-α-tocopherol for seven days. Genes showing a dose-related 
induction/repression were identified by global gene expression profiling. Our findings show that RRR- 
and all-rac-α-tocopherol share an identical transcriptional activity, i.e., induce/repress the expression 
of the same set of genes. Based on the transcriptional dose-response data, EC50 and IC50 values were 
determined for each of these genes. The feasibility of calculating a "transcriptional potency factor" of 
RRR- vs. all-rac-α-tocopherol was evaluated by dividing the EC50/IC50 of RRR-α-tocopherol by the 
corresponding EC50/IC50 of all-rac-α-tocopherol for every of the vitamin E responsive genes. Using 
this approach we have calculated 215 single biopotency ratios. Subsequently, the mean of all potency 
ratios was found to be 1.05.  
Biopotency in humans has been the subject of some debate. Several biokinetic studies comparing 
the relative bioavailability of natural and synthetic vitamin E in humans used a competitive uptake 
approach whereby both deuterated RRR- and all-rac-α-tocopheryl acetate were administered 
simultaneously [37–39]. Using this competitive approach bioavailability ratios of RRR:all-rac close to 
2:1 were found. Using a non-competitive approach, whereby deuterated RRR- and all-rac-α-tocopheryl 
acetate are administered on separate occasions to the same individual, bioavailability ratios, Cmax and 
AUC analysis, (the important parameters of bioavailability in single dose studies), were 1.35:1, 1.35:1 
and 1.33:1 respectively [40], very close to the accepted biopotency ratio of 1.36:1 derived from animal 
studies [41,42] and in stark contrast to the findings of studies using the competitive uptake approach. It 
has been argued that the competitive uptake model results in bias against all-rac, because when RRR 
and all-rac are given simultaneously in equal amounts, the actual dose would contain 75 % of 2R-
forms to compete with 25 % of 2S-forms. As the 2R-forms are preferentially selected by α-TTP for 
systemic distribution, increasing the abundance of 2R-forms lowers the probability of α-TTP binding 
to 2S-forms leading to discrimination against all-rac [43]. However when all-rac is administered 
separately to RRR, there would be 50 % each of the 2R- to 2S-forms in all-rac and hence no such 
discrimination would occur. Therefore when studied using a non-competitive approach under basal 
conditions, natural (RRR) and synthetic (all-rac) α-tocopherol are kinetically equivalent and their 
relative bioavailability conforms to the currently accepted biopotency ratio of 1.36:1 [40]. 
4. Vitamin E Regulated miRNAs 
miRNA are a class of small, noncoding RNA, that in their mature form, are single-stranded and 22 
nucleotides long. Mature miRNA post-transcriptionally affect gene expression by binding at the 3´ 
untranslated region of mRNA and inhibiting their translation into proteins [44]. It has been suggested 
that each miRNA binds on average 100 different target mRNA, allowing for post-transcriptional 
silencing of many different genes, or potentially entire pathways, by a single miRNA [45]. miRNA are 
encoded for in the genome and are, thus, liable to regulation. In order to investigate the role of dietary 
RRR-α-tocopherol on miRNA expression, we fed rats for 6 months with diets deficient or sufficient in 
vitamin E and analyzed miRNA concentrations in the liver. For this study, we selected miRNA that 
were previously shown to be involved in processes that have been associated with vitamin E, namely 
lipid metabolism (miRNA-122a) [46,47], cancer progression and inflammation (miRNA-125b)  
[48–50]. Vitamin E deficiency resulted in decreased levels of miRNA-122a and miRNA-125b. Apart 
from its role in lipid metabolism, miRNA-122 was down-regulated in rodent and human hepatocellular 
carcinomas [47]. A role for miRNA-125b in cancer development has been suggested because miRNA-
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125b was down-regulated in human prostate cancer tissues [48,49], lung cancer cell lines [51], breast 
cancer [52], and in squamous cell carcinoma of the tongue [53]. Shi and colleagues [54], on the other 
hand, found over-expression of miRNA-125b in prostate cancer cell lines and prostate cancer samples. 
A role of miRNA-125b in inflammation is supported by a study that identified tumor necrosis 
factor-alpha (TNFα) as a direct target of miRNA-125b. A decrease of miRNA-125b resulted in 
increased TNFα production and inflammation in LPS stimulated macrophages [55]. Thus, the reduced 
miRNA-125b levels observed in our vitamin E-deficient rats may be associated with an enhanced 
inflammatory response due to vitamin E deficiency, as previously described [56,57]. Overall these data 
indicate that vitamin E regulates cell signalling not only at the mRNA level but also at the miRNA 
level [58]. Although gene chip and micro-RNA technology has helped to identify vitamin E sensitive 
molecular targets, transcription factors which are specifically regulated by vitamin E have yet not been 
identified. Furthermore a receptor that specifically binds to vitamin E is currently unknown [59]. 
5. Single Nucleotide Polymorphisms in Genes Important in Vitamin E Homeostasis 
Large inter-individual variation exists in the response to vitamin E supplementation, and this may 
influence the outcome of human studies. It is our hypothesis that genetic heterogeneity is an important 
determinant of vitamin E homeostasis. Therefore we have performed an in silico search for single 
nucleotide polymorphisms (SNPs) associated with genes involved in vitamin E homeostasis. Based on 
function, the following genes were considered as candidates for vitamin E heterogeneity: α-tocopherol 
transfer protein (α-TTP), tocopherol associated protein (TAP), lipoprotein lipase (LPL), multidrug 
resistance protein 2 (MDR-2), pregnane X receptor (PXR) and members of the cytochrome P450 
family (CYP). Searches for coding SNPs were initiated from web based programs of the National 
Center for Biotechnology Information (NCBI). SNP frequencies were calculated by dividing the 
number of annotated coding SNPs by the number of base pairs in the open reading frame. Genes for α-
TTP, TAP and CYP3A5 had calculated SNP frequencies between 503 and 837 base pairs per coding 
SNP (bp/cSNP) and so are not highly polymorphic. In contrast, cSNP frequencies in LPL, MRP2, 
PXR, CYP3A4 and CYP4F2 were in the range of 100 bp/cSNP and so are highly polymorphic. Thus 
proteins involved in specific vitamin E binding are not highly polymorphic, may not influence inter-
individual variation and so may not be good candidates for population studies. Proteins involved in 
drug/lipid metabolism which indirectly influence vitamin E status are highly polymorphic, are likely to 
influence inter-individual variation and so are good candidates for population studies. In this context it 
has been shown in a biokinetic study that subjects with the apoE4 genotype differ from apoE3 subjects 
in their plasma uptake of newly absorbed α-tocopherol [60] indicating that this is an important SNP 
influencing vitamin E status. We suggest that future studies are aimed at addressing the role of such 
SNPs in vitamin E homeostasis [61]. 
6. ApoE—Vitamin E Interactions 
In Westernised societies the apoE4 genotype is associated with increased morbidity and mortality, 
and represents a significant risk factor for cardiovascular disease, late-onset Alzheimer's disease and 
other chronic disorders. ApoE is an important modulator of many stages of lipoprotein metabolism and 
traditionally the increased risk was attributed to higher lipid levels in E4 carriers. However, more 
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recent evidence demonstrates the multifunctional nature of the apoE protein and the fact that the 
impact of genotype on disease risk may be in large part due to an impact on oxidative status or the 
immunomodulatory/anti-inflammatory properties of apoE. An increasing number of studies in cell 
lines [62,63], transgenic rodents [64] and human volunteers [65,66] indicate higher oxidative stress 
and a more pro-inflammatory state associated with the epsilon4 allele [67]. Natural antioxidants 
including dietary vitamin E may counteract the adverse affect of the apoE4 genotype on oxidative 
stress and chronic inflammation. 
 
Figure 6. Proteins involved in the metabolism of α-tocopherol (α-TOH) in the lung. α -
tocopherol is distributed in the body via different lipoproteins and chylomicrons (CM). 
Cellular uptake of α-TOH is mediated by apoE and lipoprotein lipase (LPL) activity and 
their binding to several lipoprotein receptors including peripheral tissues (e.g., 
lung)receptor (LDLrec) and LDL receptor related protein 1(LRP1). Intracellular α-TOH is 
subjected to mitochondrial degradation by the cytochrome P450 family 3A (CYP3A) 
enzyme subfamily. Delivery of α-TOH to the alveolar space is facilitated by the activity of 
the α-tocopherol transfer protein (α-TTP) and ATP-binding cassette A1 (ABCA1). 
Excessive amounts of α-TOH may be also excluded via the multidrug resistance 
transporter 1 (MDR1) (according to [68]). 
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In a recent study, we observed significant lower α-tocopherol concentrations in the lung of apoE4 
compared with apoE3 transgenic mice. Genes encoding for proteins involved in peripheral  α-tocopherol transport degradation (Figure 6) are affected by the apoE genotype probably accounting 
for the lower α-tocopherol tissue concentration as observed in apoE4 mice. Infact, receptors of  
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α-tocopherol uptake including scavenger receptor B1 (SR-B1), LDL receptor (LDLrec) and LDL 
receptor related protein 1 (LRP1) were lower in apoE4 as compared to apoE3 mice. Lung mRNA 
levels of the ATP-binding cassette A1 (ABCA1) and the multidrug resistance transporter 1 (MDR1), 
surfactant proteins mediating the export of α-tocopherol, were lower in apoE4 than in apoE3 mice. In 
addition, the mRNA levels of cytochrome P450 3A (CYP3A), an enzyme family involved in the 
degradation of α-tocopherol, tended to be higher in the apoE4 as compared to the apoE3 genotype. 
Taken together our data indicate that the apoE4 may retain less α-tocopherol in the lung than apoE3 
genotype, which may in turn impact on the dietary vitamin E requirement.  
Similar to the apoE4 polymorphism, the haptoglobin 2-2 polymorphism is associated with increased 
production of reactive oxygen species and decreased tissue levels of vitamin E and importantly, 
vitamin E supplementation (d-α-tocopherol) appears to reduce cardiovascular events in individuals 
with diabetes mellitus type 2 and the Hp 2-2 genotype [69]. 
In this context a so-called personalized nutritional advice may be taken into account where 
individuals could be given dietary recommendations in terms of vitamin E considering their apoE and 
haptoglobin genotype [70]. 
The use of ‘-omic’technologies, some of which has already been discussed in this article, has 
advanced the notion of personalized nutrition. Metabolomics, a study of the complement of 
metabolites in biological samples, has been viewed as having an important role in the development of 
a nutritional phenotype for future personalized nutritional assessment [71,72]. Metabolomics offers the 
ability to determine how nutrients interact with metabolic pathways [71,73] offering insights into the 
complex relationships between diet and metabolism and diet and disease and therefore maybe able to 
define novel mechanisms of action. Both targeted and nontargeted metabolite profiling approaches can 
be used to study vitamin E status [74]. Targeted approaches to understand vitamin E physiology and 
metabolism include the use of stable isotope labeled vitamin E which allows researchers to identify 
factors that influence vitamin E status in humans including dietary, genetic, lifestyle and metabolic 
factors [35,75]. Nontargeted metabolomics is used to investigate global metabolite profiles in order to 
identify novel targets. Interestingly this approach has previously been used to investigate vitamin E 
status in murine models. Griffin et al. studied the metabolic deficits and vitamin E deficiency induced 
by neuronal ceroid lipofuscinosis in a mouse model using metabolomics and revealed how vitamin E 
supplementation could partially reverse some of the metabolic abnormalities [76]. More recently Cho 
et al. demonstrated that activation of the pregnane X receptor attenuated vitamin E metabolism to the 
usual carboxyethyl hydroxychroman (CEHC) form but discovered a novel vitamin E metabolite [77]. 
We have previously highlighted that metabolomics can be used to provide insights into how vitamin E 
can influence the human metabolome [74,75] and indeed demonstrated some interesting observations 
following a supplementation regime that are undergoing confirmation. In this regard it may be possible 
to identify novel mechanisms of vitamin E action and greatly expand our knowledge of the activities of 
vitamin E. 
 
References and Notes 
1. Karrer, P.; Fritsche, H.; Ringier, B.H.; Salomon, H. Synthesis of alpha-tocopherol. Helv. Chim. 
Acta 1938, 21, 820–825. 
Molecules 2010, 15                    
 
 
1757
2. Sure, B. Dietary requirements for reproduction: II. The existence of a specific vitamin for 
reproduction. J. Biol. Chem. 1924, 58, 693–709. 
3. Fernholz, E. On the constitution of alpha-tocopherol. J. Am. Chem. Soc. 1938, 60, 700–705. 
4. Evans, H.M.; Bishop, K.S. On the existence of a hitherto unrecognized dietary factor essential for 
reproduction. Science 1922, 56, 650–651. 
5. Mahoney, C.W.; Azzi, A. Vitamin E inhibits protein kinase C activity. Biochem. Biophys. Res. 
Commun. 1988, 154, 694–697. 
6. Fechner, H.; Schlame, M.; Guthmann, F.; Stevens, P.A.; Rustow, B. Alpha- and delta-tocopherol 
induce expression of hepatic alpha-tocopherol-transfer-protein mRNA. Biochem. J. 1998, 331, 
577–581. 
7. Stocker, A.; Zimmer, S.; Spycher, S.E.; Azzi, A. Identification of a novel cytosolic tocopherol-
binding protein: Structure, specificity, and tissue distribution. IUBMB Life 1999, 48, 49–55. 
8. Yamauchi, J.; Iwamoto, T.; Kida, S.; Masushige, S.; Yamada, K.; Esashi, T. Tocopherol-
associated protein is a ligand-dependent transcriptional activator. Biochem. Biophys. Res. 
Commun. 2001, 285, 295–299. 
9. Packer, L.; Weber, S.U.; Rimbach, G. Molecular aspects of alpha-tocotrienol antioxidant action 
and cell signalling. J. Nutr. 2001, 131, 369S–373S. 
10. Rimbach, G.; Minihane, A.M.; Majewicz, J.; Fischer, A.; Pallauf, J.; Virgli, F.; Weinberg, P.D. 
Regulation of cell signalling by vitamin E. Proc. Nutr. Soc. 2002, 61, 415–425. 
11. Fujisawa, S.; Kadoma, Y. Kinetic study of the radical-scavenging activity of vitamin E and 
ubiquinone. In Vivo 2005, 19, 1005–1011. 
12. Stocker, P.; Lesgards, J.F.; Vidal, N.; Chalier, F.; Prost, M. ESR study of a biological assay on 
whole blood: Antioxidant efficiency of various vitamins. Biochim. Biophys. Acta 2003, 1621, 1–8. 
13. Wolf, G. gamma-Tocopherol: An efficient protector of lipids against nitric oxide-initiated 
peroxidative damage. Nutr. Rev. 1997, 55, 376–378. 
14. Gottstein, T.; Grosch, W. Model study of different antioxidant properties of α- and γ-tocopherol 
in fats. Fat Sci. Technol. 1990, 92, 201–206. 
15. Jung, M.Y.; Min, D.B. Effects of oxidized α-, γ- and δ−tocopherol on the oxidative stability of 
purified soybean oil. J. Food Sci. 1990, 55, 1464–1465. 
16. Christen, S.; Woodall, A.A.; Shigenaga, M.K.; Southwell-Keely, P.T.; Duncan, M.W.; Ames, 
B.N. Gamma-tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-
tocopherol: Physiological implications. Proc. Natl. Acad. Sci. USA 1997, 94, 3217–3222. 
17. Patel, A.; Liebner, F.; Netscher, T.; Mereiter, K.; Rosenau, T. Vitamin E chemistry. Nitration of 
non-alpha-tocopherols: Products and mechanistic considerations. J. Org. Chem. 2007, 72,  
6504–6512. 
18. Traber, M.G.; Atkinson, J. Vitamin E, antioxidant and nothing more. Free Radical Biol. Med. 
2007, 43, 4–15. 
19. Frank, J. Beyond vitamin E supplementation: An alternative strategy to improve vitamin E status. 
J. Plant Physiol. 2005, 162, 834–843. 
20. Augustin, K.; Blank, R.; Boesch-Saadatmandi, C.; Frank, J.; Wolffram, S.; Rimbach, G. Dietary 
green tea polyphenols do not affect vitamin E status, antioxidant capacity and meat quality of 
growing pigs. J. Anim. Physiol. Anim. Nutr. 2008, 92, 705–711. 
Molecules 2010, 15                    
 
 
1758
21. Wiegand, H.; Boesch-Saadatmandi, C.; Wein, S.; Wolffram, S.; Frank, J.; Rimbach, G. Dietary 
flavonoids do not affect vitamin E status in growing rats. J. Anim. Physiol. Anim. Nutr. 2009,  
doi: 10.1111/j.1439-0396.2008.00910.x. 
22. Frank, J.; George, T.W.; Lodge, J.K.; Rodriguez-Mateos, A.M.; Spencer, J.P.; Minihane, A.M.; 
Rimbach, G. Daily consumption of an aqueous green tea extract supplement does not impair liver 
function or alter cardiovascular disease risk biomarkers in healthy men. J. Nutr. 2009, 139, 58–62. 
23. Azzi, A.; Gysin, R.; Kempna, P.; Munteanu, A.; Negis, Y.; Villacorta, L.; Visarius, T.; Zingg, 
J.M. Vitamin E mediates cell signaling and regulation of gene expression. Ann.NY Acad Sci. 
2004, 1031, 86–95. 
24. Boscoboinik, D.; Szewczyk, A.; Azzi, A. Alpha-tocopherol (vitamin E) regulates vascular smooth 
muscle cell proliferation and protein kinase C activity. Arch. Biochem. Biophys. 1991, 286,  
264–269. 
25. Boscoboinik, D.; Szewczyk, A.; Hensey, C.; Azzi, A. Inhibition of cell proliferation by alpha-
tocopherol. Role of protein kinase C. J. Biol. Chem. 1991, 266, 6188–6194. 
26. Fischer, A.; Pallauf, J.; Gohil, K.; Weber, S.U.; Packer, L.; Rimbach, G. Effect of selenium and 
vitamin E deficiency on differential gene expression in rat liver. Biochem. Biophys. Res. Commun. 
2001, 285, 470–475. 
27. Barella, L.; Muller, P.Y.; Schlachter, M.; Hunziker, W.; Stocklin, E.; Spitzer, V.; Meier, N.; de 
Pascual-Teresa, S.; Minihane, A.M.; Rimbach, G. Identification of hepatic molecular mechanisms 
of action of alpha-tocopherol using global gene expression profile analysis in rats. Biochim. 
Biophys. Acta 2004, 1689, 66–74. 
28. Rimbach, G.; Fischer, A.; Stoecklin, E.; Barella, L. Modulation of hepatic gene expression by 
alpha-tocopherol in cultured cells and in vivo. Ann. NY Acad. Sci. 2004, 1031, 102–108. 
29. Hundhausen, C.; Frank, J.; Rimbach, G.; Stoecklin, E.; Muller, P.Y.; Barella, Y. Effect of vitamin 
E on cytochrome P450 mRNA levels in cultured hepatocytes (HepG2) and in rat liver. Cancer 
Genomics Proteomics 2006, 3, 183–190. 
30. Murray, M. In vitro and in vivo studies of the effect of vitamin E on microsomal cytochrome P450 
in rat liver. Biochem. Pharmacol. 1991, 42, 2107–2114. 
31. Mustacich, D.J.; Gohil, K.; Bruno, R.S.; Yan, M.; Leonard, S.W.; Ho, E.; Cross, C.E.; Traber, 
M.G. Alpha-tocopherol modulates genes involved in hepatic xenobiotic pathways in mice. J. 
Nutr. Biochem. 2009, 20, 469–476. 
32. Nier, B.; Weinberg, P.D.; Rimbach, G.; Stocklin, E.; Barella, L. Differential gene expression in 
skeletal muscle of rats with vitamin E deficiency. IUBMB Life 2006, 58, 540–548. 
33. Rota, C.; Rimbach, G.; Minihane, A.M.; Stoecklin, E.; Barella, L. Dietary vitamin E modulates 
differential gene expression in the rat hippocampus: Potential implications for its neuroprotective 
properties. Nutr. Neurosci. 2005, 8, 21–29. 
34. Barella, L.; Rota, C.; Stocklin, E.; Rimbach, G. Alpha-tocopherol affects androgen metabolism in 
male rat. Ann. N. Y. Acad Sci. 2004, 1031, 334–336. 
35. Lodge, J.K. Vitamin E bioavailability in humans. J. Plant Physiol. 2005, 162, 79– 96. 
36. Muller, P.Y.; Netscher, T.; Frank, J.; Stoecklin, E.; Rimbach, G.; Barella, L. Comparative 
quantification of pharmacodynamic parameters of chiral compounds (RRR- vs. all-rac-alpha 
Molecules 2010, 15                    
 
 
1759
tocopherol) by global gene expression profiling. J. Plant Physiol. 2005, 162, 811–817, Copyright 
Elsevier (reproduced with permission). 
37. Acuff, R.V.; Thedford, S.S.; Hidiroglou, N.N.; Papas, A.M.; Odom, T.A., Jr. Relative 
bioavailability of RRR- and all-rac-alpha-tocopheryl acetate in humans: Studies using deuterated 
compounds. Am. J. Clin. Nutr. 1994, 60, 397–402. 
38. Burton, G.W.; Traber, M.G.; Acuff, R.V.; Walters, D.N.; Kayden, H.; Hughes, L.; Ingold, K.U. 
Human plasma and tissue alpha-tocopherol concentrations in response to supplementation with 
deuterated natural and synthetic vitamin E. Am. J. Clin. Nutr. 1998, 67, 669–684. 
39. Traber, M.G.; Winklhofer-Roob, B.M.; Roob, J.M.; Khoschsorur, G.; Aigner, R.; Cross, C.; 
Ramakrishnan, R.; Brigelius-Flohe, R. Vitamin E kinetics in smokers and nonsmokers. Free 
Radical Biol. Med. 2001, 31, 1368–1374. 
40. Proteggente, A.R.; Turner, R.; Majewicz, J.; Rimbach, G.; Minihane, A.M.; Kramer, K.; Lodge, 
J.K. Noncompetitive plasma biokinetics of deuterium-labeled natural and synthetic alpha-
tocopherol in healthy men with an apoE4 genotype. J. Nutr. 2005, 135, 1063–1069. 
41. Weiser, H.; Vecchi, M. Stereoisomers of alpha-tocopheryl acetate. II. Biopotencies of all eight 
stereoisomers, individually or in mixtures, as determined by rat resorption-gestation tests. Int. J. 
Vitam. Nutr. Res. 1982, 52, 351–370. 
42. Weiser, H.; Vecchi, M.; Schlachter, M. Stereoisomers of alpha-tocopheryl acetate. III. 
Simultaneous determination of resorption-gestation and myopathy in rats as a means of evaluating 
biopotency ratios of all-rac- and RRR-alpha-tocopheryl acetate. Int. J. Vitam. Nutr. Res. 1985, 55, 
149–158. 
43. Cohn, W. Evaluation of vitamin E potency. Am. J. Clin. Nutr. 1999, 69, 156–158. 
44. Boyd, S.D. Everything you wanted to know about small RNA but were afraid to ask. Lab. Invest. 
2008, 88, 569–578. 
45. Lewis, B.P.; Burge, C.B.; Bartel, D.P. Conserved seed pairing, often flanked by adenosines, 
indicates that thousands of human genes are microRNA targets. Cell 2005, 120, 15–20. 
46. Esau, C.; Davis, S.; Murray, S.F.; Yu, X.X.; Pandey, S.K.; Pear, M.; Watts, L.; Booten, S.L.; 
Graham, M.; McKay, R.; Subramaniam, A.; Propp, S.; Lollo, B.A.; Freier, S.; Bennett, C.F.; 
Bhanot, S.; Monia, B.P. miR-122 regulation of lipid metabolism revealed by in vivo antisense 
targeting. Cell Metab. 2006, 3, 87–98. 
47. Kutay, H.; Bai, S.; Datta, J.; Motiwala, T.; Pogribny, I.; Frankel, W.; Jacob, S.T.; Ghoshal, K. 
Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J. Cell. 
Biochem. 2006, 99, 671–678. 
48. Ozen, M.; Creighton, C.J.; Ozdemir, M.; Ittmann, M. Widespread deregulation of microRNA 
expression in human prostate cancer. Oncogene 2008, 27, 1788–1793. 
49. Porkka, K.P.; Pfeiffer, M.J.; Waltering, K.K.; Vessella, R.L.; Tammela, T.L.; Visakorpi, T. 
MicroRNA expression profiling in prostate cancer. Cancer Res. 2007, 67, 6130–6135. 
50. Sonkoly, E.; Wei, T.; Janson, P.C.; Saaf, A.; Lundeberg, L.; Tengvall-Linder, M.; Norstedt, G.; 
Alenius, H.; Homey, B.; Scheynius, A.; Stahle, M.; Pivarcsi, A. MicroRNAs: Novel regulators 
involved in the pathogenesis of Psoriasis? PloS One 2007, 2, e610. 
Molecules 2010, 15                    
 
 
1760
51. Nagayama, K.; Kohno, T.; Sato, M.; Arai, Y.; Minna, J.D.; Yokota, J. Homozygous deletion 
scanning of the lung cancer genome at a 100-kb resolution. Genes Chromosomes Cancer 2007, 
46, 1000–1010. 
52. Iorio, M.V.; Ferracin, M.; Liu, C.G.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, 
M.; Fabbri, M.; Campiglio, M.; Menard, S.; Palazzo, J.P.; Rosenberg, A.; Musiani, P.; Volinia, S.; 
Nenci, I.; Calin, G.A.; Querzoli, P.; Negrini, M.; Croce, C.M. MicroRNA gene expression 
deregulation in human breast cancer. Cancer Res. 2005, 65, 7065–7070. 
53. Wong, T.S.; Liu, X.B.; Wong, B.Y.; Ng, R.W.; Yuen, A.P.; Wei, W.I. Mature miR-184 as 
Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin. Cancer Res. 2008, 
14, 2588–2592. 
54. Shi, X.B.; Xue, L.; Yang, J.; Ma, A.H.; Zhao, J.; Xu, M.; Tepper, C.G.; Evans, C.P.; Kung, H.J.; 
deVere White, R.W. An androgen-regulated miRNA suppresses Bak1 expression and induces 
androgen-independent growth of prostate cancer cells. Proc. Natl. Acad. Sci. USA 2007, 104, 
19983–19988. 
55. Tili, E.; Michaille, J.J.; Cimino, A.; Costinean, S.; Dumitru, C.D.; Adair, B.; Fabbri, M.; Alder, 
H.; Liu, C.G.; Calin, G.A.; Croce, C.M. Modulation of miR-155 and miR-125b levels following 
lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to 
endotoxin shock. J. Immunol. 2007, 179, 5082–5089. 
56. Lim, Y.; Vasu, V.T.; Valacchi, G.; Leonard, S.; Aung, H.H.; Schock, B.C.; Kenyon, N.J.; Li, 
C.S.; Traber, M.G.; Cross, C.E. Severe vitamin E deficiency modulates airway allergic 
inflammatory responses in the murine asthma model. Free Radical Res. 2008, 42, 387–396. 
57. Yamaoka, S.; Kim, H.S.; Ogihara, T.; Oue, S.; Takitani, K.; Yoshida, Y.; Tamai, H. Severe 
Vitamin E deficiency exacerbates acute hyperoxic lung injury associated with increased oxidative 
stress and inflammation. Free Radical Res. 2008, 42, 602–612. 
58. Gaedicke, S.; Zhang, X.; Schmelzer, C.; Lou, Y.; Doering, F.; Frank, J.; Rimbach, G. Vitamin E 
dependent microRNA regulation in rat liver. FEBS lett. 2008, 582, 354–546. 
59. Brigelius-Flohe, R. Vitamin E: The shrew waiting to be tamed. Free Radical Biol. Med. 2009, 46, 
543–554. 
60. Lodge, J.K.; Hall, W.L.; Jeanes, Y.M.; Proteggente, A.R. Physiological factors influencing 
vitamin E biokinetics. Ann.NY Acad. Sci. 2004, 1031, 60–73. 
61. Doring, F.; Rimbach, G.; Lodge, J.K. In silico search for single nucleotide polymorphisms in 
genes important in vitamin E homeostasis. IUBMB Life 2004, 56, 615–620. 
62. Huebbe, P.; Jofre-Monseny, L.; Boesch-Saadatmandi, C.; Minihane, A.M.; Rimbach, G. Effect of 
apoE genotype and vitamin E on biomarkers of oxidative stress in cultured neuronal cells and the 
brain of targeted replacement mice. J. Physiol. Pharmacol. 2007, 58, 683–698. 
63. Jofre-Monseny, L.; de Pascual-Teresa, S.; Plonka, E.; Huebbe, P.; Boesch-Saadatmandi, C.; 
Minihane, A.M.; Rimbach, G. Differential effects of apolipoprotein E3 and E4 on markers of 
oxidative status in macrophages. Br. J. Nutr. 2007, 97, 864–871. 
64. Jofre-Monseny, L.; Loboda, A.; Wagner, A.E.; Huebbe, P.; Boesch-Saadatmandi, C.; Jozkowicz, 
A.; Minihane, A.M.; Dulak, J.; Rimbach, G. Effects of apoE genotype on macrophage 
inflammation and heme oxygenase-1 expression. Biochem. Biophys. Res. Commun. 2007, 357, 
319–324. 
Molecules 2010, 15                    
 
 
1761
65. Dietrich, M.; Hu, Y.; Block, G.; Olano, E.; Packer, L.; Morrow, J.D.; Hudes, M.; Abdukeyum, G.; 
Rimbach, G.; Minihane, A.M. Associations between apolipoprotein E genotype and circulating 
F2-isoprostane levels in humans. Lipids 2005, 40, 329–334. 
66. Majewicz, J.; Rimbach, G.; Proteggente, A.R.; Lodge, J.K.; Kraemer, K.; Minihane, A.M. Dietary 
vitamin C down-regulates inflammatory gene expression in apoE4 smokers. Biochem. Biophys. 
Res. Commun. 2005, 338, 951–955. 
67. Jofre-Monseny, L.; Minihane, A.M.; Rimbach, G. Impact of apoE genotype on oxidative stress, 
inflammation and disease risk. Mol. Nutr. Food Res. 2008, 52, 131–145, Copyright Wiley-VCH 
Verlag GmbH & Co. KGaA (reproduced with permission). 
68. Huebbe, P.; Jofre-Monseny, L.; Rimbach, G. Alpha-tocopherol transport in the lung is affected by 
the apoE genotype--studies in transgenic apoE3 and apoE4 mice. IUBMB Life 2009, 61, 453–456. 
69. Milman, U.; Blum, S.; Shapira, C.; Aronson, D.; Miller-Lotan, R.; Anbinder, Y.; Alshiek, J.; 
Bennett, L.; Kostenko, M.; Landau, M.; Keidar, S.; Levy, Y.; Khemlin, A.; Radan, A.; Levy, A.P. 
Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged 
individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: A prospective 
double-blinded clinical trial. Arterioscler. Throm. Vasc. Biol. 2008, 28, 341–347. 
70. Lovegrove, J.A.; Gitau, R. Personalized nutrition for the prevention of cardiovascular disease: A 
future perspective. J. Hum. Nutr. Diet. 2008, 21, 306–316. 
71. Zeisel, S.H.; Freake, H.C.; Bauman, D.E.; Bier, D.M.; Burrin, D.G.; German, J.B.; Klein, S.; 
Marquis, G.S.; Milner, J.A.; Pelto, G.H.; Rasmussen, K.M. The nutritional phenotype in the age 
of metabolomics. J. Nutr. 2005, 135, 1613–1616. 
72. German, J.B.; Bauman, D.E.; Burrin, D.G.; Failla, M.L.; Freake, H.C.; King, J.C.; Klein, S.; 
Milner, J.A.; Pelto, G.H.; Rasmussen, K.M.; Zeisel, S.H. Metabolomics in the opening decade of 
the 21st century: Building the roads to individualized health. J. Nutr. 2004, 134, 2729–2732. 
73. Go, V.L.; Nguyen, C.T.; Harris, D.M.; Lee, W.N. Nutrient-gene interaction: Metabolic genotype-
phenotype relationship. J. Nutr. 2005, 135, 3016S–3020S. 
74. Lodge, K. Targeted and nontargeted approaches for metabolite profiling in nutritional research. 
Proc. Nutr. Soc. 2010, 69, 1–8. 
75. Lodge, J.K. Mass spectrometry approaches for vitamin E research. Biochem. Soc. Trans. 2008, 
36, 1066–1070. 
76. Griffin, J.L.; Muller, D.; Woograsingh, R.; Jowatt, V.; Hindmarsh, A.; Nicholson, J.K.; Martin, 
J.E. Vitamin E deficiency and metabolic deficits in neuronal ceroid lipofuscinosis described by 
bioinformatics. Physiol. Genomics 2002, 11, 195–203. 
77. Cho, J.Y.; Kang, D.W.; Ma, X.; Ahn, S.H.; Krausz, K.W.; Luecke, H.; Idle, J.R.; Gonzalez, F.J. 
Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon 
PXR activation. J. Lipid Res. 2009, 50, 924–937. 
 
Sample Availability: Please contact the authors. 
© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. 
This article is an open-access article distributed under the terms and conditions of the Creative 
Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). 
